1
|
Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns. Ann Dermatol Venereol 2024; 151:103243. [PMID: 38325268 DOI: 10.1016/j.annder.2023.103243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/06/2023] [Accepted: 09/05/2023] [Indexed: 02/09/2024]
Affiliation(s)
- M Amini-Adle
- Dermatology Department, Centre Léon Bérard, Lyon, France.
| | - J-P Arnault
- Dermatology Department, Centre Hospitalo-Universitaire, Amiens Picardie, France
| | - F Aubin
- Université de Bourgogne-Franche-Comté, Dermatology Department, Head of the Skin Cancer Unit, Centre Hospitalo-Universitaire de Besançon, Besançon, France; INSERM UMR RIGHT 1098, Besançon, France
| | - N Beneton
- Dermatology Department, Centre Hospitalier, Le Mans, France
| | - G Bens
- Dermatology Department, Centre Hospitalier, Orléans, France
| | - F Brunet-Possenti
- Dermatology Department, Centre Hospitalo-Universitaire Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - P Célerier
- Dermatology Department, Centre Hospitalier La Rochelle-Ré-Aunis, La Rochelle, France
| | - J Charles
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Crumbach
- Dermatology Department, Centre Léon Bérard, Lyon, France
| | - S Dalac
- Dermatology Department, Centre Hospitalo-Universitaire, Dijon, France
| | - S Darras
- Dermatology Department, Centre Hospitalier de Boulogne-sur-Mer, France
| | - J De Quatrebarbes
- Dermatology Department, Centre Hospitalier Annecy Genevois, Annecy, France
| | - M Dinulescu
- Dermatology Department, Centre Hospitalo-Universitaire, Rennes, France
| | - C Dutriaux
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | - C Gaudy
- Dermatology Department, Centre Hospitalo-Universitaire, Marseille, France
| | - E Gérard
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | | | - F Granel-Brocard
- Dermatology Department, Hôpitaux de Brabois Allée de Morvan, Vandoeuvre Les Nancy, France
| | - F Grange
- Dermatology Department, Centre Hospitalier, Valence, France
| | - T Jouary
- Dermatology Department, Hôpital François Mitterrand, Pau, France
| | - N Kramkimel
- Dermatology Department, Centre Hospitalo-Universitaire Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - C Lebbé
- Dermatology Department, Centre Hospitalo-Universitaire Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Y Le Corre
- Dermatology Department, Centre Hospitalo-Universitaire Angers, France
| | - D Legoupil
- Dermatology Department, Centre Hospitalo-Universitaire Régional, Brest, France
| | - C Lesage
- Dermatology Department, Hôpital Saint Eloi, Montpellier, France
| | | | - J-M Lorphelin
- Dermatology Department, Centre Hospitalo-Universitaire, Caen, France
| | - S Mansard
- Dermatology Department, Centre Hospitalo-Universitaire, Clermont Ferrand, France
| | - L Martin
- Dermatology Department, Centre Hospitalo-Universitaire, Angers, France; Groupe Ethique de la Société Française de Dermatologie, France
| | - S Mary-Prey
- Centre Hospitalo-Universitaire Saint André, Bordeaux, France
| | - E Maubec
- Dermatology Department, Centre Hospitalo-Universitaire Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France
| | - N Meyer
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - C Mignard
- Dermatology Department, Centre Hospitalo-Universitaire, Rouen, France
| | - H Montaudie
- Dermatology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France; INSERM U1065, Team 12, Centre Méditerranéen de Médecine Moléculaire, Université Nice Côte d'Azur, Nice, France
| | - L Mortier
- Dermatology Department, Centre Hospitalier Régional Universitaire, Lille, France
| | - C Nardin
- Université de Bourgogne-Franche-Comté et Centre Hospitalier Universitaire, Besançon, France; IINSERM UMR RIGHT 1098, Besançon, France
| | | | - C Pagès Laurent
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - L Peuvrel
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - Gaelle Quereux
- Dermatology Department, Centre Hospitalo-Universitaire, Nantes Université, Nantes, France; INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France
| | - Caroline Robert
- Dermatology Department, Institut Gustave Roussy, Villejuif, France
| | - Philippe Saiag
- Dermatology Department, Centre Hospitalo-Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France
| | - Mélanie Saint-Jean
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - M Samimi
- Dermatology Department, Centre Hospitalo-Universitaire, Tours, France
| | - B Sassolas
- Institute of Oncology & Hematology, Hôpital Morvan, Centre Hospitalier Régional Universitaire, Brest, France
| | - C Scalbert
- Dermatology Department, Centre Hospitalier Ouest Réunion, Saint Paul, Ile de la Réunion, France
| | - F Skowron
- Dermatology Department, Hôpitaux Drome Nord, Romans Sur Isère, France
| | - M Steff
- Dermatology Department, Centre Hospitalier Intercommunal Robert Ballanger, Aulnay sous-Bois, France
| | - P-E Stoebner
- Dermatology Department, Centre Hospitalo-Universitaire, Nîmes, France
| | - S Trablesi
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Visseaux
- Polyclinique Reims Bezannes, Bezannes, France
| | - O Zehou
- Dermatology Department, Centre Hospitalo-Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - A Boespflug
- Dermatology Department, Centre Hospitalier Henri Mondor, Villejuif, France
| |
Collapse
|
2
|
Khelef K, Maubec E, Jeudy G, Bonniaud B, Pham-Ledard A, Herms F, Aubin F, Beneton N, Dinulescu M, Jannic A, Duval-Modeste A, Archier E, Berthin C, Grange F, Arnault J, Heidelberger V, Moncourier M, Mansard S, Brunet-Possenti F, Triller R, Pracht M, Dumas M, Lauche O, Mortier L, Bedane C, Dalac Rat S. Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study. J Eur Acad Dermatol Venereol 2024; 38:e71-e73. [PMID: 37595320 DOI: 10.1111/jdv.19435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 08/11/2023] [Indexed: 08/20/2023]
Affiliation(s)
- K Khelef
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - E Maubec
- Service de Dermatologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France
- Campus de Bobigny-Université Sorbonne Paris Nord, Bobigny, France
- UMR 1124, Campus Saint Germain des Prés, Paris, France
| | - G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - B Bonniaud
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - A Pham-Ledard
- Service de Dermatologie, CHU de Bordeaux, Bordeaux, France
- Université de Bordeaux, Bordeaux, France
| | - F Herms
- Service de Dermatologie, Hôpital Saint-Louis, APHP, Paris, France
| | - F Aubin
- Service de Dermatologie, INSERM 1098, CHU de Besançon de Franche Comté, Besançon, France
- Université de Bourgogne-Franche-Comté, Besançon, France
| | - N Beneton
- Service de Dermatologie, CH du Mans, Le Mans, France
| | - M Dinulescu
- Service de Dermatologie, Hôpital Pontchaillou, Rennes, France
| | - A Jannic
- Service de Dermatologie, Hôpital Henri-Mondor, APHP, Créteil, France
| | - A Duval-Modeste
- Service de Dermatologie, Hôpital Charles-Nicolle, Rouen, France
| | - E Archier
- Service de Dermatologie, Hôpital Saint-Joseph, Marseille, France
| | - C Berthin
- Service de Dermatologie, CHU d'Angers, Angers, France
| | - F Grange
- Service de Dermatologie, CHU de Reims, Reims, France
| | - J Arnault
- Service de Dermatologie, CHU Amiens-Picardie, Amiens, France
| | - V Heidelberger
- Service de Dermatologie, CH Robert-Ballanger, Aulnay-sous-Bois, France
| | - M Moncourier
- Service de Dermatologie, CHU de Grenoble-Alpes, Grenoble, France
| | - S Mansard
- Service de Dermatologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - R Triller
- Service de Dermatologie, Institut Franco-Britannique, Levallois-Perret, France
| | - M Pracht
- Groupe Hospitalier de St-Malo, Saint-Malo, France
| | - M Dumas
- Service de Dermatologie, CH René-Dubos, Pontoise, France
| | - O Lauche
- Clinique Clémentville, Montpellier, France
| | - L Mortier
- Service de Dermatologie, CHU de Lille, Lille, France
- INSERM U 1189, Université de Lille, Lille, France
| | - C Bedane
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - S Dalac Rat
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| |
Collapse
|
3
|
Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D'Incan M, Grange F, Braniste V, Bagot M. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023; 37:1777-1784. [PMID: 37113040 DOI: 10.1111/jdv.19134] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 03/29/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T-cell lymphoma (CTCL): Sézary syndrome (SS) or Mycosis Fungoides (MF). OBJECTIVES The real-world French OMEGA study aimed to describe effectiveness and tolerability of mogamulizumab in adult patients with CTCL, overall and according to the disease (SS or MF). METHODS In this retrospective study, patients treated with mogamulizumab for SS or MF were included from 14 French expert centres. The overall response rate (ORR) under treatment was described (primary criterion), as well as treatment use and safety data. RESULTS The 122 analysed patients (69 SS, 53 MF) were aged 66.6 ± 12.1 years at mogamulizumab initiation, and their median disease duration was 2.5 years (IQR: 1.3-5.6). Prior to treatment start, they received a median of three systemic CTCL therapies (2-5). Overall, 77.8% of patients suffered from advanced disease (Stage IIB-IVB), with frequent blood (B1/B2) involvement (67.5%). Over the treatment period (median: 4.6 months, 2.1-7.2), 96.7% of patients received all the planned mogamulizumab infusions. Among the 109 patients evaluable for effectiveness, ORR was 58.7% (95% CI [48.9-68.1]) overall, 69.5% [56.1-80.8] in SS and 46.0% [31.8-60.7] in MF. Compartmental response in the blood was observed in 81.8% [69.1-90.9] of SS patients. Skin responses were observed in 57.0% [47.0-66.5] of patients overall, 66.7% [52.9-78.6] in SS and 46.0% [31.8-60.7] in MF. The most common serious adverse drug reactions were rash (8.1% of patients) and infusion-related reactions (2.4%) which led to treatment discontinuation in 7.3% and 0.8% of patients, respectively. One patient with SS died from mogamulizumab-related tumour lysis syndrome. CONCLUSIONS This large French study confirmed the effectiveness and tolerability of mogamulizumab in SS and MF patients in routine medical practice.
Collapse
Affiliation(s)
- M Beylot-Barry
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - G Quereux
- Dermatology Department, Nantes University Hospital, University of Nantes, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, Nantes, France
| | - C Nardin
- Dermatology Department, Minjoz Hospital, CHU Besancon, Besancon, France
- INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France
| | - A-B Duval-Modeste
- Department of Dermatology, INSERM U519, Rouen University Hospital, Rouen, France
| | - O Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - S Dalac-Rat
- Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - G Dobos
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
- Department of Dermatology, HTCC, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - A Pham-Ledard
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - C Ram-Wolff
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M D'Incan
- Dermatology and Cutaneous Oncology, Estaing University Hospital, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - F Grange
- Department of Dermatology, Valence Hospital, Valence, France
| | - V Braniste
- Kyowa Kirin Pharma, Medical Affairs, Neuilly-sur-Seine, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
4
|
Skowron F, Mouret S, Seigneurin A, Montaudié H, Maubec E, Grange F, Quéreux G, Celerier P, Adle A, Dalac S, De Quatrebarbes J, Zehou O, Safia A, Muller P, Modiano P, Misery L, Litrowski N, Brunet Possenti F, Mortier L, Bens G, Hervieu A, Leduc N, Jouary T, Lesage C, Beneton N, Le Corre Y, Geoffrois L, Thomas-Beaulieu D, Khammari A, Wierzbicka-Hainaut E, Leccia M. La pandémie COVID-19 est associée à des mélanomes diagnostiqués à un stade plus avancé. Annales de Dermatologie et de Vénéréologie - FMC 2022. [PMCID: PMC9748166 DOI: 10.1016/j.fander.2022.09.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
5
|
Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance A, Grange F, Meyer N, Joshi A, Billan S, Zhang P, Gumuscu B, Swaby RF, Grob JJ. Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]. Ann Oncol 2022; 33:853. [PMID: 35690517 DOI: 10.1016/j.annonc.2022.05.517] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- B G M Hughes
- Cancer Care Services, Royal Brisbane and Women's Hospital, Herston; University of Queensland, Brisbane, Australia.
| | - E Munoz-Couselo
- Hospital Vall D Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - L Mortier
- University of Lille, Inserm U 1189, CHU Lille, Lille, France
| | | | - R Gutzmer
- Department of Dermatology and Allergy, Skin Cancer Center Hannover, Medizinische Hochschule Hannover, Hanover; Mühlenkreiskliniken, Ruhr University Bochum Campus Minden, Minden, Germany
| | - O Roshdy
- Jewish General Hospital, Montreal, Canada
| | | | - J Schachter
- Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel
| | - A Arance
- Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
| | - F Grange
- Dermatology Department, Center Hospitalier Universitaire de Reims-Hôpital Robert Debre, Reims
| | - N Meyer
- Dermatology, Institut Universitaire du Cancer and CHU de Toulouse, Toulouse, France
| | - A Joshi
- Department of Medical Oncology, Townsville University Hospital, Townsville, Australia
| | - S Billan
- The Head and Neck Center, Oncology Department, Rambam Health Care Campus, Haifa, Israel
| | - P Zhang
- Merck & Co., Inc., Kenilworth, USA
| | | | | | - J-J Grob
- Service de Dermatologie et Cancérologie Cutanée, Aix-Marseille University, Marseille, France
| |
Collapse
|
6
|
Common M, Ehret M, Visseaux L, Colomb M, Renard F, Dutel-Charneux J, Goeldel-Brichet AL, Adnot-Desanlis L, Grange F. The use of digital dermoscopy in the surveillance of melanocytic skin lesions: A real-life retrospective study comparing university hospital and private practices. Ann Dermatol Venereol 2022; 149:251-257. [DOI: 10.1016/j.annder.2022.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 09/09/2021] [Accepted: 03/08/2022] [Indexed: 11/28/2022]
|
7
|
Munoz Couselo E, Hughes B, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance Fernandez A, Grange F, Meyer N, Joshi A, Billan S, Grob J, Zhang P, Gumuscu B, Swaby R, Mortier L. 149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
8
|
Grob J, Aubin F, Benmahammed-Bellagha L, Brunet-Possenti F, Dereure O, Dutriaux C, Duval-Modeste AB, Grange F, Jarvis C, Kramkimel N, Leccia MT, Machet L, Meyer N, Mortier L, Neidhardt EM, Robert C, Scherrer E, Spampinato A, Verdoni L, Saiag P. 1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Fredeau L, Hober C, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, Meyer N, Duval Modeste AB, Cesaire L, Neidhardt EM, Archier E, Dreno B, Lesage C, Berthin C, Kramkimel N, Grange F, De Quatrebarbes J, Stoebner P, Poulalhon N, Arnault J, Abed S, Bonniaud B, Darras S, Heidelberger V, Devaux S, Moncourier M, Misery L, Mansard S, Etienne M, Brunet-Possenti F, Jacobzone C, Lesbazeilles R, Skowron F, Sanchez J, Catala S, Samimi M, Tazi Y, Spaeth D, Gaudy-Marqueste C, Collard O, Triller R, Pracht M, Dumas M, Peuvrel L, Combe P, Lauche O, Guillet P, Reguerre Y, Kupfer-Bessaguet I, Solub D, Schoeffler A, Bedane C, Dalac S, Mortier L, Maubec E. Cémiplimab et carcinomes épidermoïdes cutanés localement évolués ou métastatiques : premières données de vie réelle. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, Grob J, Dréno B, Scheer-Senyarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudié H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guegan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Dalac S, Levy V. Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané non opérable. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Maincent O, Grange A, Criquet E, Walls B, Singh T, Ehret M, Visseaux L, Grange F. Photothérapie dynamique associée au laser CO2 fractionné en traitement des carcinomes cutanés et kératoses actiniques. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Hourbeigt K, Ehret M, Visseaux L, Durlach A, Petit A, Sanchez J, Grange A, Barbe C, Servagi-Vernat S, Grange F. Efficacité et sécurité du panitumumab seul ou en association avec la radiothérapie dans les carcinomes épidermoïdes cutanés inopérables. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Rezzag C, Common M, Criquet E, Ehret M, Visseaux L, Durlach A, Grange F. Mélanome de stade I/II inopérable : efficacité d’une immunothérapie anti-PD1. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Stefanski M, Monnier J, Le Guern A, Visseaux L, Ehret M, Colomb M, Jeudy G, Vourch M, Le Duff F, Norberciak L, Baroudjian B, Bernigaud C, Perea-Villacorta R, Mallet S, Debarbieux S, Perrot J, Grange F, Modiano P, Bahadoran P. Activité de microscopie confocale in vivo en France : étude observationnelle prospective multicentrique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Criquet E, Ehret M, Durlach A, Rezzag-Mahcene C, Common M, Visseaux L, Grange F. Éruption cutanée granulomateuse psoriasifome sous mogamulizumab : une entité particulière associée à la réponse clinique ? Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Oro S, Battistella M, d’Incan M, Rouanet J, Franck F, Vignon-Pennamen MD, Franck N, Carlotti A, Boulinguez S, Lamant L, Petrella T, Dalac S, Joly P, Courville P, Rivet J, Dereur O, Amatore F, Taix S, Grange F, Durlach A, Quéreux G, Josselin N, Moulonguet I, Mortier L, Dubois R, Maubec E, Laroche L, Michel L, Templier I, Barete S, Nardin C, Augereau O, Vergier B, Bagot M. Changements dans l’épidémiologie des lymphomes cutanés primitifs en France : une analyse de 8593 patients du registre du Groupe Français d’Etude des Lymphomes Cutanés (GFELC). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Soufir N, Benfodda M, Descamps V, Gazal S, Madjlessi-Ezra N, Colomb M, Baccard M, Archimbaud A, Renard F, Fite C, Grange A, Levy-Sitbon C, Vuong V, Jehou J, Arnoult-Coudoux E, Bachoud A, Massart-Manil S, Nicaise-Bergere C, Machuel B, Schernberg C, Lami MC, Basset-Seguin N, Lebbe C, Dupin N, Wolkenstein P, Bagot M, Saiag P, Fraitag S, Bensussan A, Marinho E, Nagore E, Kumar R, Grange F. L’algorithme MELAPRED apparaît comme un outil clef du dépistage ciblé du mélanome. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Beaudoux O, Riffaud L, Marchal A, Visseaux L, Grange F, Lebre AS. Caractérisation moléculaire des mélanomes primitifs muqueux. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Ingen-Housz-Oro S, Battistella M, d'Incan M, Rouanet J, Franck F, Vignon-Pennamen MD, Franck N, Carlotti A, Boulinguez S, Lamant L, Petrella T, Dalac S, Joly P, Courville P, Rivet J, Dereure O, Amatore F, Taix S, Grange F, Durlach A, Quéreux G, Josselin N, Moulonguet I, Mortier L, Dubois R, Maubec E, Laroche L, Michel L, Templier I, Barete S, Nardin C, Augereau O, Vergier B, Bagot M. Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry. Br J Dermatol 2020; 184:1059-1067. [PMID: 33131055 DOI: 10.1111/bjd.19644] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/28/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND Primary cutaneous lymphomas (PCLs) are a heterogeneous group of T-cell (CTCL) and B-cell (CBCL) malignancies. Little is known about their epidemiology at initial presentation in Europe and about potential changes over time. OBJECTIVES The aim of this retrospective study was to analyse the frequency of PCLs in the French Cutaneous Lymphoma Registry (GFELC) and to describe the demography of patients. METHODS Patients with a centrally validated diagnosis of primary PCL, diagnosed between 2005 and 2019, were included. RESULTS The calculated incidence was unprecedently high at 1·06 per 100 000 person-years. The number of included patients increased yearly. Most PCL subtypes were more frequent in male patients, diagnosed at a median age of 60 years. The relative frequency of rare CTCL remained stable, the proportion of classical mycosis fungoides (MF) decreased, and the frequency of its variants (e.g. folliculotropic MF) increased. Similar patterns were observed for CBCL; for example, the proportion of marginal-zone CBCL increased over time. CONCLUSIONS Changes in PCL frequencies may be explained by the emergence of new diagnostic criteria and better description of the entities in the most recent PCL classification. Moreover, we propose that an algorithm should be developed to confirm the diagnosis of PCL by central validation of the cases.
Collapse
Affiliation(s)
- G Dobos
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - A de Masson
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - C Ram-Wolff
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - M Beylot-Barry
- Dermatology Department, Université de Bordeaux, Bordeaux, France
| | - A Pham-Ledard
- Dermatology Department, Université de Bordeaux, Bordeaux, France
| | - N Ortonne
- Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France
| | - S Ingen-Housz-Oro
- Dermatology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France
| | - M Battistella
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France.,Pathology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M d'Incan
- Dermatology and Cutaneous Oncology, Estaing University Hospital, Université de Clermont-Ferrand, Clermont-Ferrand, France
| | - J Rouanet
- Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France
| | - F Franck
- Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France
| | | | - N Franck
- Dermatology Department, Cochin Hospital, AP-HP, Paris, France
| | - A Carlotti
- Pathology Department, Cochin Hospital, AP-HP, Paris, France
| | - S Boulinguez
- Dermatology Department, Cahors Hospital, Toulouse, France
| | - L Lamant
- Pathology and Cytopathology Department, Institut Universitaire du Cancer Toulouse, Toulouse, France
| | - T Petrella
- Pathology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - S Dalac
- Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - P Joly
- Dermatology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France
| | - P Courville
- Pathology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France
| | - J Rivet
- Dermatology Department, Université de Bordeaux, Bordeaux, France.,Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France
| | - O Dereure
- Dermatology Department, Montpellier University Hospital, Montpellier, France
| | - F Amatore
- Department of Dermatology and Oncodermatology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France
| | - S Taix
- Department of Pathology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France
| | - F Grange
- Dermatology Department, Robert Debré University Hospital, Reims, France
| | - A Durlach
- Pathology Department, Reims University Hospital, Reims, France
| | - G Quéreux
- Dermatology Department, Nantes University Hospital, Nantes, France
| | - N Josselin
- Pathology Department, Nantes University Hospital, Nantes, France
| | - I Moulonguet
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - L Mortier
- Dermatology Department, Claude Huriez University Hospital, INSERM U1189, Université de Lille, Lille, France
| | - R Dubois
- Pathology Department, Claude Huriez University Hospital, Lille, France
| | - E Maubec
- Dermatology Department, Avicenne Hospital, AP-HP, Paris, France
| | - L Laroche
- Dermatology Department, Avicenne Hospital, AP-HP, Paris, France
| | - L Michel
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - I Templier
- Dermatology Department, Grenoble University Hospital, Grenoble, France
| | - S Barete
- Dermatology Department, Pité-Salpêtrière Hospital, AP-HP, Paris, France
| | - C Nardin
- Dermatology Department, Minjoz Hospital, Besancon, France, INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France
| | - O Augereau
- Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France
| | - B Vergier
- Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | | |
Collapse
|
20
|
Hober C, Fredeau L, Ledard AP, Boubaya M, Herms F, Aubin F, Benetton N, Dinulescu M, Jannic A, Cesaire L, Meyer N, Modeste AD, Archier E, Lesage C, Kramkimel N, Arnault J, Grange F, Dalac S, Mortier L, Maubec E. 1086P Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experience. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1210] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
21
|
Hourbeigt K, Ehret M, Visseaux L, Durlach A, Petit A, Sanchez J, Grange‐Prunier A, Barbe C, Servagi‐Vernat S, Grange F. Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol 2020; 34:2789-2794. [DOI: 10.1111/jdv.16465] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Accepted: 03/27/2020] [Indexed: 12/27/2022]
Affiliation(s)
- K. Hourbeigt
- Department of Oncodermatology Reims University Hospital Reims France
| | - M. Ehret
- Department of Oncodermatology Reims University Hospital Reims France
| | - L. Visseaux
- Department of Oncodermatology Reims University Hospital Reims France
| | - A. Durlach
- Department of Biopathology Reims University Hospital Reims France
| | - A. Petit
- Department of Oncodermatology Reims University Hospital Reims France
| | - J. Sanchez
- Department of Oncodermatology Reims University Hospital Reims France
| | - A. Grange‐Prunier
- Department of Oncodermatology Reims University Hospital Reims France
| | - C. Barbe
- Methodological Support Unit Reims University Hospital Reims France
| | | | - F. Grange
- Department of Oncodermatology Reims University Hospital Reims France
| |
Collapse
|
22
|
D'Incan M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, Grange F, Quereux G, Templier I, Ram-Wolff C, Adamski H, Lambert C, Descours C. Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. Br J Dermatol 2020; 184:356-358. [PMID: 32810288 DOI: 10.1111/bjd.19495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Revised: 07/30/2020] [Accepted: 08/14/2020] [Indexed: 11/28/2022]
Affiliation(s)
- M D'Incan
- Department of Dermatology and Skin Oncology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - M Beylot-Barry
- Department of Dermatology, CHU de Bordeaux, Bordeaux, France
| | - P Joly
- Department of Dermatology, CHU de Rouen, Rouen, France
| | - F Grange
- Department of Dermatology, CHU de Reims, Reims, France
| | - G Quereux
- Department of Dermatology, CHU de Nantes, Nantes, France
| | - I Templier
- Department of Dermatology, CHU de Grenoble, Grenoble, France
| | - C Ram-Wolff
- Department of Dermatology, Hôpital Saint-Louis, Paris, France
| | - H Adamski
- Department of Dermatology, CHU de Rennes, Rennes, France
| | - C Lambert
- Department of Biostatistics, CHU de Clermont-Ferrand, France
| | - C Descours
- Department of Dermatology and Skin Oncology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| |
Collapse
|
23
|
Hughes B, Gonzalez RM, Basset-Seguin N, Vornicova O, Schachter J, Joshi A, Meyer N, Grange F, Piulats J, Bauman J, Chirovsky D, Zhang P, Gumuscu B, Swaby R, Grob J. Health-Related Quality of Life of Pembrolizumab for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma in KEYNOTE-629. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.360] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Stien S, Greliak A, Visseaux L, Grange F. Syndrome d’activation macrophagique sévère sous immunothérapie et thérapie ciblée du mélanome. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Soufir N, Benfodda M, Grange F, Basset-Seguin N, Descamps V, Thomas L, Grandchamp B. Test MELAPRED : une nouvelle indication chez les patients atteints de maladie de Parkinson. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
26
|
Parajuli S, Grange F, Grange A, Soufir N, Lebre AS, Paudel U. Fréquence et gravité du xeroderma pigmentosum au Népal. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Saiag P, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C. Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Grob J, Gonzalez Mendoza R, Basset-Seguin N, Vornicova O, Schachter J, Joshi A, Meyer N, Grange F, Piulats J, Bauman J, Zhang P, Gumuscu B, Swaby R, Hughes B. Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.069] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Dutriaux C, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Saiag P. An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Dequidt L, Franck N, Sanchez‐Pena P, Dalle S, Adamski H, Boulinguez S, Ingen‐Housz‐Oro S, Ram‐Wolff C, Boccara O, Bonnet N, Cortes B, Gouraud A, Grange F, Le Corre Y, Quereux G, De Masson A, Schmutz J, Skowron F, Verneuil L, Beylot‐Barry M. Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. Br J Dermatol 2019; 181:616-618. [DOI: 10.1111/bjd.17834] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- L. Dequidt
- Dermatology Department University Hospital Bordeaux France
- INSERM U1053 Bordeaux Research in Translational Oncology Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux France
| | - N. Franck
- Dermatology Department AP‐HP Cochin Hospital Paris France
| | - P. Sanchez‐Pena
- Pharmacovigilance Centre Medical Pharmacology Department University Hospital Bordeaux France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - M. Beylot‐Barry
- Dermatology Department University Hospital Bordeaux France
- INSERM U1053 Bordeaux Research in Translational Oncology Team 3 Oncogenesis of Cutaneous Lymphomas University of Bordeaux France
| |
Collapse
|
31
|
Visseaux L, Durlach A, Barete S, Ingen‐Housz‐Oro S, Ortonne N, Grange F. Response to ‘Cutaneous eruptions associated with haematological malignancies: the need for a unifying nomenclature’. J Eur Acad Dermatol Venereol 2019; 33:e193. [DOI: 10.1111/jdv.15451] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- L. Visseaux
- Service d'Oncodermatologie Hôpital Robert Debré Reims France
| | - A. Durlach
- Service de Pathologie Hôpital Maison Blanche Reims France
| | - S. Barete
- Unité Fonctionnelle de Dermatologie Hôpital La Pitié Salpêtrière Paris France
| | | | - N. Ortonne
- Service de Pathologie Hôpital Henri Mondor Créteil France
| | - F. Grange
- Service d'Oncodermatologie Hôpital Robert Debré Reims France
| |
Collapse
|
32
|
Bontoux C, De Masson A, Boccara O, Bodemer C, Fraitag S, Balme B, Franck N, Carlotti A, Comoz F, Verneuil L, Brasme JF, Duplan M, Croué A, Templier I, Beltraminelli H, Dereure O, Szablewski V, Thevenin C, Boulinguez S, Viraben R, Tournier E, Lamant L, Ortonne N, Ingen-Housz-Oro S, Beckerich F, Grange F, Durlach A, Amatore F, Frouin E, McIntyre E, Asnafi V, Kim R, Clappier E, Soulier J, Boissel N, Dombret H, Bagot M, Battistella M. Clinical aspects and outcome of lymphoblastic leukemia/lymphoma with cutaneous involvement. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30538-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Hourbeigt K, Stein S, Condamina M, Durlach A, Grange A, Visseaux L, Grange F. Kératoses actiniques inflammatoires sous panitumumab : un effet secondaire méconnu. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
34
|
Chaplain L, Blom A, Samimi M, Guillot B, Jouary T, Grob JJ, Meyer N, Zehou O, Combemale P, Lebbé C, Jeudy G, Grange F, Lacour P, Dinulescu M, Granel Brocard F, Beneton N, Aubin F, Bens G, De Quatrebarbes J, Steff M, Arnault JP, Le Corre Y, Stefan A, D’Incan M, Kramkimel N, Leccia MT, Thomas Beaulieu D, Maubec E, Robert C, Dreno B, Wierzbicka-Hainaut E, Lenormand C, Saiag P, Mortier L. Carcinome de Merkel : état des lieux du réseau CARADERM. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
35
|
Bourquin M, Visseaux L, Stien S, Condamina M, Hourbeigt K, Lesage C, Sanchez J, Barbe-Da Cunha C, Grange F. Rôle des traumatismes dans les mélanomes des paumes, des plantes et des ongles : première étude cas-témoin basée sur la population. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Deschamps O, Ram‐Wolff C, Beylot‐Barry M, Grange F, Skowron F, Dereure O, Boulinguez S, Aubin F, Ingen‐Housz‐Oro S, Bagot M. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma. Br J Dermatol 2018; 180:423-424. [DOI: 10.1111/bjd.17269] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- O. Deschamps
- Department of Dermatology Hôpital Saint‐Louis AP‐HP INSERM U976, Paris 7 University Paris France
| | - C. Ram‐Wolff
- Department of Dermatology Hôpital Saint‐Louis AP‐HP INSERM U976, Paris 7 University Paris France
| | - M. Beylot‐Barry
- Department of Dermatology Hôpital Saint‐André University of Bordeaux INSERM U1053, Team 3 Oncogenesis of Cutaneous Lymphomas Bordeaux France
| | - F. Grange
- Department of Dermatology Hôpital Robert Debré Reims France
| | - F. Skowron
- Department of Dermatology Centre Hospitalier de Valence Valence France
| | - O. Dereure
- Department of Dermatology and INSERM U1058 ‘Pathogenesis and Control of Chronic Infections’ University of Montpellier Montpellier France
| | - S. Boulinguez
- Department of Dermatology CHU Toulouse Toulouse France
| | - F. Aubin
- Department of Dermatology CHRU Besançon Besançon France
| | | | - M. Bagot
- Department of Dermatology Hôpital Saint‐Louis AP‐HP INSERM U976, Paris 7 University Paris France
| | | |
Collapse
|
37
|
Visseaux L, Durlach A, Barete S, Beylot-Barry M, Bonnet N, Chassine A, Franck N, Herve G, Leclec'h C, Machet L, Ingen-Housz-Oro S, Petrella T, Vergier B, Ortonne N, Grange F. T-cell papulosis associated with B-cell malignancy: a distinctive clinicopathologic entity. J Eur Acad Dermatol Venereol 2018; 32:1469-1475. [DOI: 10.1111/jdv.14805] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Accepted: 01/03/2018] [Indexed: 10/18/2022]
Affiliation(s)
- L. Visseaux
- Service de Dermatologie; Hôpital Robert Debré; Reims France
| | - A. Durlach
- Laboratoire Pol Bouin; Hôpital Maison Blanche; Reims France
| | - S. Barete
- Service de Dermatologie; Hôpital Pitié-Salpêtrière; Paris France
| | - M. Beylot-Barry
- Service de Dermatologie; Hôpital Saint-André; Bordeaux France
| | - N. Bonnet
- Dermatologie; Institut Paoli Calmettes; Marseille France
| | | | - N. Franck
- Service de Dermatologie; Hôpital Cochin; Paris France
| | - G. Herve
- Service de Pathologie; Hôpital Pitié-Salpêtrière; Paris France
| | - C. Leclec'h
- Service de Dermatologie; CHU d'Angers; Angers France
| | - L. Machet
- Service de Dermatologie; Hôpital Trousseau; Tours France
| | | | - T. Petrella
- Department of Hematology-Oncology; University of Montréal; Montréal Canada
| | - B. Vergier
- Service de Pathologie; Hôpital Haut-Levêque; Pessac France
| | - N. Ortonne
- Service de Pathologie; Hôpital Henri Mondor; Créteil France
| | - F. Grange
- Service de Dermatologie; Hôpital Robert Debré; Reims France
| |
Collapse
|
38
|
Espi P, Parajuli S, Benfodda M, Lebre AS, Paudel U, Grange A, Grybek V, Grange T, Soufir N, Grange F. Clinical and genetic characteristics of xeroderma pigmentosum in Nepal. J Eur Acad Dermatol Venereol 2017; 32:832-839. [DOI: 10.1111/jdv.14717] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 10/31/2017] [Indexed: 11/29/2022]
Affiliation(s)
- P. Espi
- Department of Dermatology; Robert Debré Hospital; Reims France
| | - S. Parajuli
- Department of Dermatology; Maharajgunj Medical Canpus; Tribhuvan University; Katmandu Nepal
| | - M. Benfodda
- Department of Genetics; Bichat Hospital; Paris France
- INSERM U976; Saint-Louis Hospital; Paris France
| | - A.-S. Lebre
- Department of Genetics; Maison Blanche Hospital; Reims France
| | - U. Paudel
- Department of Dermatology; Maharajgunj Medical Canpus; Tribhuvan University; Katmandu Nepal
| | - A. Grange
- Department of Dermatology; Robert Debré Hospital; Reims France
| | - V. Grybek
- Department of Genetics; Maison Blanche Hospital; Reims France
| | - T. Grange
- INSERM U1148; Bichat Hospital; Paris France
| | - N. Soufir
- Department of Genetics; Bichat Hospital; Paris France
- INSERM U976; Saint-Louis Hospital; Paris France
| | - F. Grange
- Department of Dermatology; Robert Debré Hospital; Reims France
| |
Collapse
|
39
|
Adamski H, Ingen‐Housz‐Oro S, Machet L, Carriou A, Ram‐Wolff C, Ortonne N, Le Gall F, Durlach A, Dupuis J, Dauriac C, Dupuy A, Grange F, Bagot M. Lymphomatoid papulosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: three cases. Br J Dermatol 2017; 178:e5-e6. [DOI: 10.1111/bjd.15698] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- H. Adamski
- Department of Dermatology Rennes University Hospital Rennes France
| | | | - L. Machet
- Department of Dermatology Tours University Hospital and François Rabelais University Tours France
| | - A.C. Carriou
- Department of Dermatology Rennes University Hospital Rennes France
| | - C. Ram‐Wolff
- Department of Dermatology AP‐HP St Louis Hospital Paris 7 University Paris France
| | - N. Ortonne
- Department of Pathology AP‐HP Henri Mondor Hospital Creteil France
| | - F. Le Gall
- Department of Pathology Rennes University Hospital Rennes France
| | - A. Durlach
- Laboratory of Histopathology Reims University Hospital Reims France
| | - J. Dupuis
- Lymphoid Malignancies Unit AP‐HP Henri Mondor Hospital Creteil France
| | - C. Dauriac
- Department of Hematology Rennes University Hospital Rennes France
| | - A. Dupuy
- Department of Dermatology Rennes University Hospital Rennes France
| | - F. Grange
- Department of Dermatology Reims University Hospital Reims France
| | - M. Bagot
- Department of Dermatology AP‐HP St Louis Hospital Paris 7 University Paris France
| |
Collapse
|
40
|
Guichard G, Grange F, Saiag P, Charles J, Dreno B, Guillot B, Lacour JP, Gaudy C, Monestier S, Hesse S, Khammari A, Visseaux L, Kramkimel N, Finet A, Picard A, Malissen N, Troin L, Magis Q, Richard MA, Grob JJ. Il n’y a pas de surtoxicité des BRAF-MEK inhibiteurs lorsqu’ils sont prescrits immédiatement après l’arrêt des anti-PD1. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Deschamps O, Ram-Wolf C, Beylot-Barry M, Grange F, Skowron F, Dereure O, Boulinguez S, Aubin F, Oro S, Bagot M. Traitement des mycosis fongoïde et syndrome de Sézary par la romidepsine : une série de 32 cas du Groupe français d’étude des lymphomes cutanés (GFELC). Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Lheure-Barbier C, Kramkimel N, Plee J, Franck N, Goldman-Levy G, Vanhaecke C, Dupin N, Aractingi S, Grange F, Guegan S. Mélanomes primitifs localement avancés et inopérables en rémission complète après traitement néoadjuvant par anti-PD1 : 3 cas. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Bohelay G, Husson B, Ortonne N, Braun T, Levy A, Poirier E, Bayaram M, Grange F, Maubec E, Laroche L. Mutation L265P MYD88, outil diagnostique du lymphome lymphoplasmocytaire cutané satellite de maladie de Waldenström. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Dequidt L, Franck N, Adamski H, Boulinguez S, Dalle S, Oro S, Bonnet N, Cortes B, Grange F, Quéreux G, Ram-Wolff C, Skowron F, Verneuil L, Beylot-Barry M. Lymphomes cutanés apparus sous biothérapie : une série de 21 cas du GFELC. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Gardette E, Maraval A, Brunet-Possenti F, Quereux G, Beltraminelli H, Templier I, Hodel J, Scherman E, Durot E, Bagot M, Pham-Ledard A, Grange F, Beylot-Barry M, Ingen-Housz-Oro S. Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. J Eur Acad Dermatol Venereol 2017; 31:e498-e501. [PMID: 28543967 DOI: 10.1111/jdv.14358] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- E Gardette
- Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - A Maraval
- Neuroradiology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - F Brunet-Possenti
- Dermatology, AP-HP, Bichat Hospital, Paris, France.,French Study Group of Cutaneous Lymphoma, GFELC, Paris, France
| | - G Quereux
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, University Hospital of Nantes, Nantes, France
| | - H Beltraminelli
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, Inselspital, Bern University Hospital, Bern, France
| | - I Templier
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, University Hospital of Grenoble, Grenoble, France
| | - J Hodel
- Neuroradiology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - E Scherman
- Lymphoid Malignancies Unit, AP-HP, Henri Mondor Hospital, Créteil, France
| | - E Durot
- Hematology, University Hospital of Reims, Reims, France
| | - M Bagot
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, AP-HP, Saint-Louis Hospital, Paris, France
| | - A Pham-Ledard
- Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - F Grange
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, University Hospital of Reims, Reims, France
| | - M Beylot-Barry
- French Study Group of Cutaneous Lymphoma, GFELC, Paris, France.,Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - S Ingen-Housz-Oro
- Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,French Study Group of Cutaneous Lymphoma, GFELC, Paris, France
| |
Collapse
|
46
|
Visseaux L, Durlach A, Barete S, Bayaram M, Beylot-Barry M, Bonnet N, Chassine A, Combemale P, Dhaille F, Franck N, Hervé G, Leclec’h C, Machet L, Oro S, Petrella T, Vergier B, Ortonne N, Grange F. Papulose T associée aux hémopathies B. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Riffaud L, Barbe C, Beaudoux O, Le Clainche A, Soufir N, Grange F. Facteurs pronostiques et incidence des mélanomes muqueux primitifs : une étude française basée sur la population. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
48
|
Adamski H, Oro S, Machet L, Carriou A, Ortonne N, Le Gall F, Durlach A, Haioun C, Dauriac C, Dupuy A, Grange F, Bagot M. Papulose lymphomatoïde et leucémie lymphoïde chronique, une association très rare : 3 observations. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Basset Seguin N, Poulalhon N, Saiag P, Monestier S, Bagot M, Guillot B, Robert C, Meyer N, Khammari A, Grange F, Dutriaux C, Dréno B. Fréquence des résistances au vismodegib dans une série de 207 patients atteints de carcinomes basocellulaires localement avancés. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
50
|
Mermin D, Bonnet N, Bouabdallah R, Duval-Modeste AB, Mortier L, Oro S, Ram-Wolff C, Barete S, Dalle S, Maubec E, Quereux G, Templier I, Bagot M, Grange F, Vergier B, Merlio JP, Pham-Ledard A, Dousseau A, Maillard A, Beylot-Barry M. Lenalidomide dans les lymphomes cutanés primitifs B diffus à grandes cellules type-jambe en rechute ou réfractaires : PHRC REV-LEG. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|